Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.

Expert opinion on pharmacotherapy - 1 Jan 2016

Brower Jeffrey V, Robins H Ian

Abstract excerpt

INTRODUCTION: Brain metastases (BM) are a common and lethal complication of non-small cell lung cancer (NSCLC) with up to 40% experiencing this complication. The use of erlotinib, a small molecule epidermal growth factor receptor (EGFR) inhibitor, holds promise in this somewhat refractory cohort of patients, and has become the subject of active clinical investigation. AREAS COVERED: This review covers the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Brain Neoplasms
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials, Phase I as Topic

Share to Clinical Trials, Phase II as Topic

Share to Clinical Trials, Phase III as Topic

Share to ErbB Receptors

Share to Erlotinib Hydrochloride

Source

Identifiers

PMID: 26967582
DOI: 10.1517/14656566.2016.1165206

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Erlotinib for the treatment of brain metastases in non-small cell lung cancer.PMID 26967582Read ↗

The effectiveness of erlotinib against brain metastases in non-small cell lung cancer patients.Semantic proximity Read ↗

Efficacy of Tyrosine Kinase Inhibitors in ALK and EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain.Semantic proximity Read ↗

Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

Commentary: Treatment Considerations for Patients With Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer Brain Metastases in the Era of Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read ↗

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.Semantic proximity Read ↗

A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.Semantic proximity Read ↗

Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.Semantic proximity Read ↗

EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.Semantic proximity Read ↗

The diagnosis and treatment of brain metastases in EGFR mutant lung cancer.Semantic proximity Read ↗

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.